Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 1

Interventions

Magnetic Resonance Spectroscopy 13pembrolizumab 8Nivolumab 8Biopsy 8Radiotherapy 7Specimen Handling 5Cyclophosphamide 5Temozolomide 4Radiosurgery 4fludarabine 3X-Rays 3Surgical Procedures, Operative 3Rituximab 3Paclitaxel 3Leukapheresis 3Ipilimumab 3Fluorodeoxyglucose F18 3Dexamethasone 3Bevacizumab 3Aspirin 3perflutren 2alovudine 2Vaccines 2Tirzepatide 2Positron-Emission Tomography 2Phantoms, Imaging 2Omeprazole 2Niacinamide 2Neoadjuvant Therapy 2Metastasectomy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × azeliragon × 90 days × Clear all
NCT06831526 2026-05-29

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Washington University School of Medicine

Phase EARLY_PHASE1 Recruiting
12 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡